HomeTagsJohnson & Johnson

Tag: Johnson & Johnson

biotech

Johnson & Johnson prostate cancer drug receives CHMP positive opinion

Jim Cornall - February 5, 2026

biotech

First precision therapy prostate cancer drug approved

Jim Cornall - December 17, 2025

biotech

CRS programme to feature Poolbeg Pharma trial

Jim Cornall - December 11, 2025

biotech

“Turning point in how we treat EGFR-mutated lung cancer”

Jim Cornall - September 10, 2025

biotech

Johnson & Johnson aiming to revolutionise plaque psoriasis treatment

Jim Cornall - July 24, 2025

biotech

Johnson & Johnson receives Priority Review for high-risk non-muscle invasive bladder cancer treatment

Jim Cornall - July 22, 2025

- Advertisement -

spot_img

Latest Articles

biotech

Base to Base biotech podcast 78: A new treatment for erectile dysfunction, and nanotechnology for knee osteoarthritis

biotech

Kovina Therapeutics awarded $2.3m grant for first-in-class HPV cancer therapy

biotech

IL-23 inhibitor shows improvement in spinal pain and stiffness in axial psoriatic arthritis study

biotech

Canada looks to biotech as a national priority

biotech

Starving cancer’s fuel source could boost treatment effectiveness